NCT04705844撤回3 期
Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Adalimumab (Humira) or Placebo in Patients With Mild-Moderate COVID-19
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 主要终点
- Establish whether treatment with adalimumab is associated with a lower rate of progression to severe disease as defined by severe illness or critical illness, or death in outpatient subjects with COVID-19
研究概览
简要总结
Clinical study of Humira (adalimumab) or placebo in subjects with mild-moderate COVID-19
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Randomized, Double-Blind, Placebo-Controlled
入排标准
- 年龄范围
- 40 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject (or their legally authorized representative) is willing and able to provide written informed consent prior to performing study procedures.
- •Understands and agrees to comply with planned study procedures.
- •Male or non-pregnant female adult ≥60 and ≤ 80years of age OR male or non-pregnant female adult ≥40 and ≤80 years, with one or more of the following risk factors (asthma, diabetes, hypertension, obesity [body mass index >30], cardiovascular disease).
- •Has a laboratory-confirmed SARS-CoV-2 infection as determined by FDA-approved rapid diagnostic (e.g., polymerase chain reaction [PCR]) assay within the preceding 7 days (168 hours).
- •Has at least 2 COVID-19 related symptoms on the 14-question COVID-19 questionnaire.
- •Has peripheral capillary oxygen saturation (SpO2) >93% by pulse oximetry.
- •C-reactive protein (CRP) >50 mg/L or lymphopenia (<1.5×109/L) or neutrophilia (>7.5×109/L).
- •Agrees to the collection of blood and urine samples, nasal swabs , and non-invasive oxygen monitoring (via pulse oximeter) per protocol.
- •Willing to receive 4 injections at separate sites on the thigh or abdomen.
- •Women of childbearing potential must agree to either abstinence or use of at least one primary form of contraception (not including hormonal contraception) from the time of screening through Day 29 following randomization.
- •Agrees to not participate in any other clinical trial (both pharmacologic and other types of interventions) through Day 29 following randomization
排除标准
- •Received or contemplating any COVID-19 vaccine or participated in a COVID-19 vaccine trial.
- •Subject is considered to be in their last few weeks of life prior to this acute illness.
- •History of pulmonary alveolar proteinosis.
- •History of hematopoietic stem cell transplant or solid organ transplant.
- •Previous malignancy and lymphoproliferative disorders (within the last 5 years) with the exception of stable prostate cancer and basal cell carcinoma.
- •Chronic obstructive pulmonary disease on long-term oxygen therapy - subjects with forced expiratory volume in 1 second known to be <50% will also be excluded.
- •Demyelinating disease.
- •Known history of hepatitis B, HIV, or untreated hepatitis C infection
- •Severe hepatic impairment or known cirrhosis - Child-Pugh score B or higher.
- •Acute kidney injury Stage 3
- •Tuberculosis or other severe infections such as (non-COVID-19) sepsis, abscesses, fungal superinfection and opportunistic infections requiring treatment.
- •Positive Quantiferon Gold test at screening
- •Moderate or severe heart failure (New York Heart Association Class III/IV).
- •Treatment with monoclonal antibodies targeting cytokines (e.g., TNF inhibitors [adalimumab, infliximab, etanercept, golimumab, certolizumab]; anti-IL-1 [e.g., anakinra, canakinumab]; anti-IL-6 or anti-IL-6r [e.g., tocilizumab, sarilumab, sitlukimab]; or T-cells [e.g., abatacept]) in past 90 days (5 half-lives of the drug), or contemplating treatment with any of these agents during the trial period.
- •Treatment with monoclonal antibodies targeting B-cells (e.g., rituximab, and including any targeting multiple cell lines including B-cells) in the 3 months prior to screening.
- •Received GM-CSF agents (e.g., sargramostim) within 2 months prior to screening.
- •Treatment with other immunosuppressants in the 4 weeks prior to screening and in the judgment of the Investigator, the risk of immunosuppression with adalimumab is larger than the risk of COVID-
- •Treatment with small molecule tyrosine kinase inhibitors (e.g., baricitinib, ibrutinib, acalabrutinib, imatinib, gefitinib), in the 4 weeks prior to screening.
- •Received or contemplating receipt of any live vaccine or any investigational vaccine in the 4 weeks prior to screening.
- •Current participation or previous participation in any other clinical trial within 30 days prior to randomization.
- •Subjects with known hypersensitivity to adalimumab or excipients of adalimumab as stated in the label.
- •Pregnant female
- •Lactating female
- •Women of childbearing potential who do not agree to either abstinence or use of at least one primary form of contraception (not including hormonal contraception) from the time of screening through Day 29 following randomization.
研究组 & 干预措施
Adalimumab
Experimental
single dose of adalimumab(160 mg administered as 4×40 mg subcutaneous [SC] injections at separate sites on the thigh or abdomen
干预措施: Adalimumab (Drug)
Placebo
Placebo Comparator
single dose of placebo (administered as 4×40 mg subcutaneous [SC] injections at separate sites on the thigh or abdomen
干预措施: Placebo (Drug)
结局指标
主要结局
Establish whether treatment with adalimumab is associated with a lower rate of progression to severe disease as defined by severe illness or critical illness, or death in outpatient subjects with COVID-19
时间窗: 28 Days
Proportion of subjects with the following outcomes attributed to COVID-19 from time of first dose through Day 28 following randomization: * Death * Alive and hospitalized or requiring supplemental oxygen for ≥1 hour * Alive and not hospitalized or requiring supplemental oxygen for ≥1 hour
Assess the safety of adalimumab in subjects with COVID-19
时间窗: 28 Days
Incidence of Grade 3 and Grade 4 clinical adverse events (AEs) from first dose through Day 28 following randomization
次要结局
- Assess the impact of treatment with adalimumab on clinical course of COVID-19 infection(120 Days)
研究者
相似试验
Unknown
3 期
Novaferon for COVID-19 Treatment Trial (NCTT-005)Covid19NCT04708158Genova Inc.385
已完成
3 期
A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19COVID-19NCT04397562Biocad206
已完成
3 期
Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)Covid19NCT06729593National Institute of Allergy and Infectious Diseases (NIAID)87
已完成
4 期
Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or FeetPsoriasisNCT00735787Abbott81
已完成
1 期
REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumoniaCOVID19ARDSNCT04468971Cellenkos, Inc.45